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Judging a Character by the Company It Keeps*Milind Y. Desai, MD, Christine L. Jellis, MD, PHDN oninvasive cardiac imaging specialists arethe detectives of the cardiology world.Using different modalities and techniques,
we are able to piece together clues and use circum-
stantial evidence to deduce the likely culprit. Like
all investigators, we are subject to our own intrinsic
biases; however, the prejudice of experience may be
our most valuable quality. When it comes to assess-
ment of cardiac masses, accurate diagnosis relies on
pattern recognition and “guilt by association.” In
the criminal world, suspects are often judged by
the company they keep, and our typical method of
cardiac mass differentiation is no different. However,
suspicions must be proven beyond reasonable doubt.
Cardiac magnetic resonance (CMR) is well positioned
to provide more objective evidence to support our
clinical suspicions and help close the case.
Just like with criminals, there are grades of danger
among cardiac masses. Our ﬁrst role is to determine if
it is something we need to be concerned about and act
upon immediately. Can it be observed over time, or
can it be ignored and quickly forgotten? The funda-
mental principle is to determine whether a mass is
benign or malignant. Large masses with features
of invasion or irregular margins are obviously the
most concerning. Other suspicious characteristics
include: broad-based attachment, loss of tissue
planes, traversing of cardiac chambers, tissue hetero-
geneity with surrounding enhancement, and extrac-
ardiac abnormalities that may represent primary
disease or metastatic spread. Typically, these features
reﬂect malignant disease and have a much poorer
prognosis. Treatment might be targeted at relief of
symptomatic obstruction because resection with*Editorials published in JACC: Cardiovascular Imaging reﬂect the views
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Cardiovascular Imaging or the American College of Cardiology.
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disclose.curative intent is typically not feasible. If a mass is
suspected of being malignant, autopsy studies high-
light that secondary malignancy, as opposed to a pri-
mary cardiac tumor, is 20 to 40 timesmore common (1).
Location can also help determine the cause of the
tumor, whether it is a direct invasion from breast or
lung malignancies, venous extension from a renal cell
carcinoma, hematological seeding from remote pri-
mary malignancies, or aggressive mediastinal tumors.
In contrast, primary intracardiac tumors are more
likely to be benign (2) and therefore have a better
prognosis. In these situations, intervention is
reserved for relief of obstruction or if there are
associated issues such as embolization or thrombus
formation. In the majority of cases, complete resec-
tion is possible and remedial.
Intracardiac thrombi are typically diagnosed by
the “company they keep.” A left atrial mass in the
setting of mitral stenosis or atrial ﬁbrillation is a
thrombus until proven otherwise. Left ventricular
masses associated with apical aneurysms or other
regional wall motion abnormalities are highly sug-
gestive of mural thrombi. In this setting, anti-
coagulation and watchful waiting may be a reasonable
management strategy; however, once the milieu for
thrombus development has been proven, lifelong
anticoagulation is usually warranted in those without
risk of bleeding. Lastly, although vegetations may be
difﬁcult to differentiate from thrombi, clinical corre-
lation should provide some clues to etiology.
The principles outlined here can be applied to any
modality of cardiac imaging for initial cardiac mass
assessment. However, the adoption of CMR into our
imaging repertoire has enabled further differentiation
of cardiac masses on the basis of multiplanar imaging
and tissue characterization. Different CMR sequences
exploit speciﬁc mass characteristics, which are largely
determined by their vascularity, their solid or cystic
nature, and associated structures. Noncontrast
T1- and T2-weighted turbo spin echo and cine imag-
ing allow assessment of mass size, location, mobility,
surrounding structures, and dynamic information
TABLE 1 Stratiﬁcation of Cardiac Masses on The Basis of Typical CMR Characteristics
Thrombus Benign Tumor Malignant Tumor
Structural and functional assessment: gradient echo cine imaging
Size Small Small, usually well circumscribed Large, irregular margins
Uniformity of
tissue signal
Homogeneous Homogeneous or heterogeneous
(due to regions of necrosis)
Heterogeneous
Mobile Yes Yes No
Surrounding structures
and location
Associated with left ventricular dysfunction,
regional wall motion abnormalities,
venous catheters, left atrial appendage,
or mitral stenosis
Usually well circumscribed, can cause
mass effect, often located in a
typical position such as the left
atrium or interatrial septum
Invasion of surrounding structures without
adherence to tissue planes, unusual
locations and involving multiple cardiac
chambers, extracardiac disease
(including lung or breast masses)
Other Reduces in size after anticoagulation Associated features such as
pericardial/pleural effusions
Tissue characterization
T1-weighted turbo
spin echo sequence
Hyperintense Variable intensity
– Lipomas ¼ hyperintense
– Cysts ¼ hypointense
Variable intensity
T2-weighted turbo
spin echo sequence
Isointense/hypointense (old thrombus) Isointense/hyperintense Isointense/hyperintense
T2 STIR-weighted sequence Isointense/hypointense (old thrombus) Isointense/hyperintense
(cystic lesions and hemangiomas)
Isointense/hyperintense (osteosarcomas,
angiosarcomas, and leiomyosarcomas)
Fat saturation sequence Isointense Isointense/hypointense (lipomas) Isointense/hypointense (liposarcomas)
First-pass perfusion
(saturation-recovery
fast gradient-echo
sequence)
No Yes Yes
T1 Look-Locker sequence
(post-contrast)
Hypointense with longer T1 time Hyperintense with shorter T1 time
(longer T1 time if cystic)
Hyperintense with shorter T1 time
Delayed gadolinium
enhancement
No (may have enhancement of adjacent
myocardial scar)
Yes (especially hemangiomas, ﬁbromas
and rhabdomyomas)
Yes (especially angiosarcomas)
CMR ¼ cardiac magnetic resonance; STIR ¼ short-inversion-time inversion-recovery; TI ¼ inversion time.
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907regarding obstruction. T2-weighted short-inversion-
time inversion-recovery sequences enable assess-
ment of water content to differentiate edematous
tissue or cystic structures from other tissue, including
fat (3). First-pass perfusion imaging allows assess-
ment of mass vascularity (4), whereas late gadolinium
enhancement (LGE) imaging demonstrates the pres-
ence of extracellular matrix and is typically absent in
the setting of thrombus (5).SEE PAGE 896CMR is widely used for mass assessment; however,
there have been few studies validating this practice.
The study by Pazos-López et al. (6) in this issue of
iJACC is the biggest to date and provides timely
clariﬁcation with a unique perspective. They report a
retrospective analysis of 116 cases in which they
differentiate tumor (n ¼ 42) from thrombus (n ¼ 84),
and then benign (n ¼ 17) from malignant (n ¼ 25)
tumor, on the basis of CMR tissue characterization
with a variety of widely available commercial se-
quences. On cine imaging, the authors were able to
show consistent patterns whereby thrombi were
smaller, more homogeneous, and less mobile than
tumors (all p < 0.001). Compared with normalmyocardium, tumors demonstrated signal hyper-
intensity/isointensity on T2, ﬁrst-pass perfusion, and
LGE (all p < 0.0001) with short inversion times (TI),
whereas thrombi were hypointense with long TI. On
further stratiﬁcation, benign masses were smaller and
had less perfusion and LGE (all p < 0.03) than their
malignant counterparts. The authors reported that
accuracy of differentiation between tumors and
thrombi was high at 95%; distinguishing between
benign and malignant neoplasms was less accurate at
79%.
T1 mapping is a rapidly expanding CMR technique
that has shown utility across a broad range of condi-
tions, particularly in the assessment of myocardial
ﬁbrosis. To date, there has been limited use of this
novel technique for characterization of intracardiac
masses (7). Despite low numbers (n ¼ 30), Pazos-
López et al. (6) were able to show a reduction in post-
contrast T1 time with tumors compared with thrombi.
This ﬁnding can be explained by the relative absence
of extracellular matrix present in tumor burden
compared with soft tissue. However, it seems likely
that the T1 value of organized or chronic thrombus
might be lower due to increased ﬁbrosis, thereby
resulting in less differentiation between the 2
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908pathologies. Further validation of this promising
technique is required. Fat saturation prepulses are
useful adjuncts to standard CMR sequences. They
suppress the signal of fatty tissue, which can be
useful for differentiation of lipomatous septal hy-
pertrophy, lipomas, and liposarcomas from other
cystic or solid cardiac tumors (4). This technique was
not routinely used by Pazos-López et al. (6); how-
ever, its targeted inclusion in a CMR mass protocol
may be useful.
The study by Pazos-López et al. (6) is limited by
small study numbers. However, their favorable re-
sults suggest that tissue characterization with CMR is
worthwhile for improved accuracy in deﬁning cardiac
masses. Further prospective data may facilitate vali-
dation of a diagnostic algorithm to optimize the CMR
sequences used for the greatest accuracy and shortest
scan time. Once data are collected from a larger
cohort, a more detailed analysis of speciﬁc tumor
features with CMR tissue characterization may be
possible. Our current assessment is limited to deter-
mining whether masses are benign or malignant;
accurate subtyping remains difﬁcult. Although Pazos-
López et al. (6) mention pathological diagnosis as a
criteria for differentiation between thrombus and
tumor, no data are presented to verify if pathological
classiﬁcation was performed. The absence of histo-
logical validation of CMR sequences remains a sig-
niﬁcant limiting issue of this paper and the technique
in general. An important factor, which the paper
does not address, is that some patients are unable
to receive gadolinium-based contrast due to previous
allergy or impaired renal function, which mayprecipitate nephrogenic systemic ﬁbrosis. Non-
contrast CMR may still prove useful in these subjects
because multiplanar imaging techniques can over-
come the limitations of echocardiographic acoustic
windows and allow better assessment of structures,
including the right ventricle, pulmonic valve, poste-
rior atria walls, venous drainage, and great vessels.
Although computed tomography scans can also be
used for assessment of cardiac tumors, their limited
functional information and radiation dose give CMR a
signiﬁcant advantage.
Like forensic teams examining for clues, we need
to recognize the footprints of speciﬁc cardiac masses.
A general schema for CMR stratiﬁcation is listed in
Table 1. CMR arms the physician detective with
additional clues regarding the malignant potential of
a mass on the basis of tissue characterization, the
intracardiac company that it keeps, and any extrac-
ardiac “criminal associates.” Pazos-López et al. (6)
have provided a timely assessment of CMR accuracy
in differentiation between thrombi and benign tu-
mors or malignant intracardiac masses, but ongoing
histological validation of CMR sequences is required
before further noninvasive subtyping can be per-
formed with certainty. As with criminals, cardiac
masses do not always follow the rules, and deferring
diagnosis to biopsy remains necessary in many cases.
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